COMMUNIQUÉS West-GlobeNewswire
-
Orphazyme A/S: Stabilisation measures taken
05/12/2017 - 19:00 -
Cleartronic’s (CLRI) ReadyOp Software Platform Now Being Used by LA Metro
05/12/2017 - 19:00 -
Ozempic® (semaglutide) approved in the US
05/12/2017 - 18:49 -
Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2017
05/12/2017 - 18:01 -
Essilor : Nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2017
05/12/2017 - 18:01 -
In new survey of patients, Inspire examines clinical trials, genetic testing
05/12/2017 - 18:00 -
AFA Invites Teens To Enter Its 2018 “Teens For Alzheimer’s Awareness” College Scholarship Essay Contest
05/12/2017 - 17:46 -
RadNet, Inc. to Present at 10th Annual LD Micro Main Event Conference in Los Angeles on December 7th
05/12/2017 - 17:41 -
Kalytera Confirms No Material Change in Operations
05/12/2017 - 17:10 -
ABILITY Network Helps Skilled Nursing Providers Streamline the Triple Check Process
05/12/2017 - 16:18 -
Texas Health IT company wants to make the US healthcare market competitive again
05/12/2017 - 16:00 -
RedHill Biopharma Provides 2017 Year-End Business Update
05/12/2017 - 15:30 -
Transactions concluded by management
05/12/2017 - 15:21 -
Adverum Biotechnologies Begins Patient Enrollment in the ADVANCE Phase 1/2 Clinical Trial for A1AT Deficiency
05/12/2017 - 15:00 -
Chembio Receives $8.5 Million Commitment from Bio-Manguinhos to Purchase Components for Production of DPP® Assays in Brazil during 2018
05/12/2017 - 14:50 -
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
05/12/2017 - 14:45 -
CV Sciences, Inc. Repays Installment Obligation on Convertible Debt
05/12/2017 - 14:45 -
Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
05/12/2017 - 14:35 -
Antibacterial Benefits of PEKK for Orthopedic Applications Detailed in Study of 3D-Printed OsteoFab® Structures
05/12/2017 - 14:30
Pages